摘要
目的:评价重组人白细胞介素-2(rhIL-2)对复治肺结核的辅助治疗效果。方法:将43例复治肺结核患者随机分为观察组23例,对照组20例。2组抗结核治疗方案一致,观察组另外应用rHIL-2,2×105U皮下注射60d。结果:2个月痰菌阴转率观察组优于对照组(P<0.05),7个月时CD4和CD4/CD8比值均明显增高,与对照组比较差别有统计学意义(P<0.05)。白细胞介素-2可溶性受体(sIL-2R)观察组明显下降,与对照组比较差别有统计学意义(P<0.05)。结论:rhIL-2辅助治疗复治肺结核有效。
Objective: To study the effects of rhIL-2 on the adjuvent treatment of reactivation tuberculosis. Methods: Forty-three patients with reactivation tuberculosis were randomly divided into trial group (23 cases) and control group (20 cases). 2 × 105 units rhIL-2 were injected subcutaneously for 60 days in trial group besides the same antitubercular agents administrated in both two groups. Results: The negative rate of sputum in trial group was higher than that in control group after two months (P < 0.05). The CD4 and CD4/CD8 ratio in trial group increased significantly 7 months after the treatment and it was significantly different compared with control group (P < 0.05). The level of serum receptor sIL-2R in trial group decreased significantly and it was significantly different compared with control group (P < 0.05). Conclusion: rhIL-2 is effective as adjuvent treatment of reactivation tuberculosis.
出处
《天津医药》
CAS
北大核心
2005年第6期342-344,共3页
Tianjin Medical Journal
